hotspot -WSS

hotspot

author：entertainment 2025-09-27 19:28:19 - browse：1893

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Health tech startups drop sharply from 2021 highs

focus

WSS

Why an extreme heat and wildfire smoke combination can be so dangerous

What to know about Saharan dust affecting the US and how it can affect health

Data show record exodus of life scientists from academia

Covid vaccines: Private market messier than government rollout

FDA advisers vote against ALS treatment from BrainStorm

Marvel Studios reveals new trailer for 'The Marvels': Watch here

focus

hotspot

entertainment

The high cost of giving birth even with insurance

FDA seeks to regulate lab

Psychedelics group wrestles with new pharma identity

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Guidelines to prevent youth baseball injuries need more muscle

Kaiser Permanente unions announce official strike date

United colonoscopy coverage change 'may cost lives,' doctors say

How the Dana

23andMe had bad news about my health. I wish a person had delivered it

In new study, freeze

focus

Medicaid, Medicare dual

Did you have Obamacare on your GOP debate bingo card?

Court strikes down limits on filming of police in Arizona

Mindstrong's demise and the future of mental health care

Kaiser Permanente unions announce official strike date

How artificial intelligence is being used to detect, treat cancer

hotspot

Wikipedia

focus

hotspot